Can Synthetic Biology Save Us? This Scientist Thinks So. Mergers and acquisitions of companies, such as Thermo Fisher Scientific and Life Technologies, and biotech start-ups, like Cambridge Therapeutics Group, have the potential to create some of the most innovative new companies in Washington. But it will also be necessary to carry out R&D projects to improve the efficiency of these new organizations. It is important to create transparency between the start-ups and those entering the industry and make sure that market failures are not allowed to drive bad decisions.
These are the key topics discussed today in a live interactive session on biotechnology and pharmaceuticals, which focused on Synthetic Biology. The discussion was moderated by Kiran R. Desai, professor of biochemistry and cellular biology at the Johns Hopkins University School of Medicine and Scientific Director of the Johns Hopkins Center for Applied Molecular Evolution.
The panel included:
Joe Muscatel, co-founder and co-CEO of Cambridge Therapeutics Group
Mikhail Lenchikov, M.D., Ph.D., deputy director for scientific, medical and regulatory affairs at the National Institutes of Health’s Center for Biophotonics and Biophotonics Medicine (CBB)
Robert Hawkins, Ph.D., president and CEO of Akamai Technologies, Inc.